Table 3 Changes of echocardiographic parameters from baseline to Week 24.

From: Effects of canagliflozin on cardiac remodeling and hemodynamic parameters in patients with type 2 diabetes mellitus

 

Baseline Mean (SD)

24-Week mean (SD)

p value

LV mass (g)

182.1 ± 51.8

187.1 ± 51.0

0.520

LV EDV (mL)

105.7 ± 30.7

108.2 ± 33.1

0.649

LV ESV (mL)

41.0 ± 17.8

41.0 ± 17.2

0.982

Left ventricular Ejection Fraction (%)

61.8 ± 8.3

62.8 ± 7.5

0.308

Cardiac output (mL)

4.9 ± 1.6

4.9 ± 1.9

0.971

Stroke volume index

36.6 ± 10.2

38.4 ± 10.7

0.345

LV IVRT (ms)

94.2 ± 11.3

96.5 ± 23.0

0.525

DT (ms)

220.9 ± 48.3

226.1 ± 46.1

0.492

E (m/s)

0.8 ± 0.2

0.7 ± 0.2

0.262

A (m/s)

0.9 ± 0.2

0.9 ± 0.2

0.622

E/e' ratio

11.3 ± 3.2

9.1 ± 2.9

< 0.001

LV GLS (%)

16.6 ± 2.8

18.0 ± 3.4

< 0.001

LA Volume (mL)

51.8 ± 16.5

46.6 ± 15.3

< 0.001

PALS (%)

23.6 ± 5.8

28.2 ± 7.4

< 0.001

LA SRs

1.3 ± 0.4

1.4 ± 0.5

0.006

LA SRe

0.9 ± 0.3

1.3 ± 0.4

0.000

LA SRa

1.3 ± 0.5

1.3 ± 0.6

0.611

LA stiffness

0.5 ± 0.2

0.4 ± 0.2

< 0.001

  1. EDV end-diastolic volume, ESV end-systolic volume, IVRT isovolumic relaxation time, DT deceleration time, GLS global longitudinal strain, PALS peak atrial longitudinal strain, LA SRs systolic LA strain rate, LA SRe early LA strain rate, LA SRa late LA strain rate.